Krystal Biotech, Inc. (KRYS): Results of Operations and Financial Condition
Krystal Biotech, Inc. (KRYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results $119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance she
How this was made
The 30-second read
Why it matters
Traders can update models for near-term revenue durability (VYJUVEK), balance-sheet runway (cash and investments), and the probability-weighted timing of multiple upcoming clinical catalysts (notably IOLITE top-line in 4Q 2026).
Market read
The 8-K provides concrete commercial KPIs (revenue, gross margin, reimbursement approvals, prescriber base) and a dated catalyst schedule for 2H 2026 and 4Q 2026, which can drive repricing of biotech risk and timing.
What to watch
The filing emphasizes enrollment and expected timelines for multiple programs, but does not provide interim efficacy results for several registrational studies, leaving execution and regulatory risk as key uncertainties.
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
VYJUVEK net product revenue increased 24% from the prior-year quarter, gross margin was 95%, net income increased to $54.8 million, and cash, cash equivalents and investments totaled $1.1 billion.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| VYJUVEK global net product revenueGAAP | $119.2 million | – | 24% |
| Product revenue, netGAAP | $119.2 million | – | – |
| Gross marginother | 95% | – | – |
| Cost of goods soldGAAP | $6.4 million | – | – |
| Research and development expensesGAAP | $14.5 million | – | – |
| Research and development stock-based compensationGAAP | $2.5 million | – | – |
| Selling, general, and administrative expensesGAAP | $39.9 million | – | – |
| Selling, general, and administrative stock-based compensationGAAP | $11.7 million | – | – |
| Net incomeGAAP | $54.8 million | – | – |
| Net income per common share, basicGAAP | $1.85 per common share | – | – |
| Net income per common share, dilutedGAAP | $1.79 per common share | – | – |
| Product revenue, net for the six months ended June 30GAAP | $235.6 million | – | – |
| VYJUVEK global revenue since launchother | $965.9 million | – | – |
| Cash, cash equivalents and investmentsGAAP | $1.1 billion | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| VYJUVEKDurable demand, broad reimbursement access, increasing use as a lifelong wound management therapy, and momentum in Germany, France, and Japan. | $119.2 million | – | 24% |
2H 2026 and 2027 outlook
- NoteCommercial launches of VYJUVEK in Italy and Spain before year end.
- NoteMultiple additional VYJUVEK marketing authorization applications in 2H 2026, including Switzerland and Australia.
- NoteIOLITE top-line data readout in 4Q 2026.
- NoteComplete enrollment of approximately 60 patients in EMERALD-1 before year end.
- NoteComplete enrollment of approximately five patients and report interim KB407 study results before year end.
- NoteAlignment with the FDA on KB407 registrational study design and statistical analysis plan in 4Q 2026.
- NoteInitiate the KB407 registrational study in 2027.
- NoteReport interim KB408 study results in 2027.
- NoteEnroll approximately seven patients and report interim KB111 study results before year end.
- NoteDiscuss KB111 results, the HHD-specific severity scale, and study designs with the FDA following completion of HALITE-1 to enable a registrational study start in 2027.
- NoteComplete enrollment in the final KYANITE-1 dose expansion cohort later this year.
- NoteReport updated interim KYANITE-1 results and potential registrational study plans in 1H 2027.
- NoteProvide an interim clinical update on intratumoral KB707 in Gorlin syndrome and potential development plans later this year.
- NoteInitiate a Phase 2 study of KB304 in 2027.
What drove it
- The Company recorded $119.2 million in global VYJUVEK net product revenue, an increase of 24% compared to the prior year second quarter.
- The Company secured over 730 reimbursement approvals for VYJUVEK and expanded its prescriber base to include over 640 unique prescribers as of the end of 2Q 2026.
- International VYJUVEK activity reflected growing physician engagement, patient starts, and prescription demand in Germany, France, and Japan.
- The Company reported a 95% gross margin for the quarter.
- In KYANITE-1, inhaled KB707 plus pembrolizumab achieved an objective response rate of 31% and a disease control rate of 75% in advanced NSCLC.
Concerns
- Pricing discussions with German reimbursement authorities are expected to continue until at least 2H 2026, while French pricing discussions are expected to continue into 2027.
- Pricing discussions in the UK are underway.
- The Company is still enrolling patients in multiple development programs, including EMERALD-1, SERPENTINE-1, HALITE-1, and the final KYANITE-1 dose expansion cohort.
- KB407 registrational study design and statistical analysis remain subject to alignment with the FDA.
What to watch
- IOLITE top-line data in 4Q 2026.
- EMERALD-1 enrollment progress toward approximately 60 patients before year end.
- KB407 interim results before year end and FDA alignment in 4Q 2026.
- VYJUVEK commercial launches in Spain and Italy before year end.
- Updated KYANITE-1 interim results and potential registrational plans in 1H 2027.
- The interim clinical update for intratumoral KB707 in Gorlin syndrome later this year.
Balance sheet and cash flow
- Cash, cash equivalents and investments totaled $1.1 billion as of June 30, 2026.
Analysis
Krystal reported $119.2 million in global VYJUVEK net product revenue for the second quarter of 2026, up 24% compared with the prior-year second quarter. Product revenue, net was $119.2 million versus $96.0 million, while gross margin was 95%. The release attributes United States performance to durable demand, broad reimbursement access, and increasing use of VYJUVEK as a lifelong wound management therapy. International activity in Germany, France, and Japan was described as gaining momentum through physician engagement, patient starts, and prescription demand.
Profitability remained positive. Cost of goods sold was $6.4 million versus $7.2 million, research and development expense was $14.5 million versus $14.4 million, and selling, general, and administrative expense was $39.9 million versus $35.1 million. Net income was $54.8 million, compared with $38.3 million, with diluted net income per common share of $1.79 compared with $1.29. The Company ended the quarter with $1.1 billion in cash, cash equivalents and investments.
Commercial execution remains centered on VYJUVEK. The Company had secured over 730 reimbursement approvals and expanded the prescriber base to over 640 unique prescribers as of the end of 2Q 2026. The next commercial catalysts are expected launches in Spain and Italy before year end and multiple additional marketing authorization applications in 2H 2026, including Switzerland and Australia. Pricing and reimbursement discussions remain a key execution item, with Germany expected to continue until at least 2H 2026 and France into 2027.
The pipeline has several scheduled data and operational milestones. IOLITE for KB803 was fully enrolled in April and has a top-line data readout targeted for 4Q 2026. The Company expects to complete enrollment of approximately 60 patients in EMERALD-1 before year end, while KB407 is expected to produce interim results before year end and receive FDA alignment on a registrational design in 4Q 2026. The Company also expects interim KB111 results before year end and updated KYANITE-1 results with potential registrational plans in 1H 2027.
Oncology data provide an additional development focus. In advanced NSCLC, inhaled KB707 plus pembrolizumab achieved an objective response rate of 31% and a disease control rate of 75%, with median duration of response and progression free survival not reached as of data cut-off. The Company plans to complete the final KYANITE-1 dose expansion cohort later this year. The balance sheet, positive net income, high gross margin, continued VYJUVEK growth, and concentration of clinical milestones in the second half of 2026 frame the reported period.
Management, verbatim
Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts.
Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech
VYJUVEK is not only changing the standard of care for DEB patients around the world, it is also giving us the ability to advance high-conviction rare disease programs across the eye, lung, and skin with focus and discipline.
Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech
Not in the filing
stated, not guessed- Total revenue separate from product revenue, net
- Operating income or loss
- Operating margin
- Non-GAAP financial measures
- Operating cash flow
- Free cash flow
- Debt balance
- Share repurchases
- Dividends
- Prior-quarter comparisons for reported quarterly metrics
- Prior-year gross margin
- Six-month cost of goods sold, operating expenses, net income, and earnings per share, as the filing text is truncated after the six-month product revenue line
- Financial revenue, gross-margin, operating-expense, or tax-rate guidance
- Prior outlook or guidance for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Krystal’s 2Q 2026 financial and operating results plus business updates across its VYJUVEK commercial franchise and pipeline programs.
Ticker impact
Krystal Biotech reported 2Q 2026 VYJUVEK revenue of $119.2M (+24% YoY), 95% gross margin, and $1.1B cash, plus 2H 2026 launch and readout plans.
Moderately positive bias for the stock as traders price in stronger commercial traction and clearer 2H 2026 catalysts.
The filing includes multiple specific, time-bound updates: revenue growth, reimbursement/prescriber expansion, expected international launches before year-end, and top-line readouts scheduled for 4Q 2026, all of which are actionable for biotech risk/reward positioning.
Market effects
Reinforces demand and reimbursement momentum for gene therapy in rare dermatology, potentially supporting sentiment toward similar commercial-stage rare-disease assets.
Highlights Europe pricing and reimbursement discussions (Germany, France, Italy, Spain) and UK pricing underway, which can influence regional rare-disease payer expectations.
International launch progress (Germany, France, Japan) and planned Spain/Italy launches before year-end can affect global rare-disease commercialization benchmarks.
Counterpoint
High gross margin and revenue growth may already be partially anticipated; the bigger swing factor is whether upcoming registrational readouts (4Q 2026) validate pipeline expansion beyond VYJUVEK.
Key entities
- issuerKrystal Biotech, Inc.
NASDAQ-listed company reporting 2Q 2026 results and providing pipeline and international launch updates.
- productVYJUVEK (beremagene geperpavec-svdt, B-VEC)
Commercial gene therapy for dystrophic epidermolysis bullosa; reported revenue growth, reimbursement approvals, and launch momentum.
- clinical_programIOLITE (KB803)
Registrational study fully enrolled in April, targeting a top-line data readout in 4Q 2026.
- clinical_programEMERALD-1 (KB801)
Registrational study continuing enrollment, targeting completion of ~60 patients before year-end.
